Key insights
- ConnectM Technology Solutions enacted a 1-for-32 reverse stock split. While reverse splits can temporarily boost share price, they often signal underlying weakness and may negatively impact investor sentiment towards the stock. The broader market impact is negligible.
ConnectM Technology Solutions, Inc. (OTCQX:CNTM) enacted a 1-for-32 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on Friday. The move follows approval by both the company’s stockholders and its board of directors on January 15.
As a result of the reverse split, every 32 shares of pre-split common stock have been automatically reclassified into one share of common stock. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive one whole share for any fraction created by the reverse split.
The company’s common stock is expected to begin trading on a post-split basis on the OTCQX under the temporary ticker symbol “CNTMD” and a new CUSIP number, 207944208, at market open on Monday. After 20 business days, the ticker symbol will revert to “CNTM.”
Stockholders holding shares in book-entry form do not need to take any action. Those with shares through banks, brokers, or other nominees will have their positions automatically adjusted, subject to broker processes. Stockholders with physical stock certificates will receive instructions from the company’s transfer agent, Continental Stock Transfer & Trust Company, regarding the exchange for post-split shares.
This information is based on a press release statement contained in the company’s filing with the Securities and Exchange Commission.
In other recent news, ON Semiconductor has received an upgrade from BofA Securities, which raised its stock rating to Buy from Neutral. The firm also increased its price target to $85, citing the company’s strong pipeline, including AI power and Treo products, and a buyback commitment of $6 billion over the next three years. Meanwhile, Ascendis Pharma has closed an exercise window for its outstanding warrants, leading to the issuance of 399,438 new ordinary shares and an increase in the company’s share capital. Additionally, Ascendis Pharma’s board has granted 22,480 warrants to employees, with an exercise price of $240.52 per share, to vest over the next four years.
Graphjet Technology announced the resignation of four independent directors, with the company clarifying that the resignations were not due to any disagreements with management or governance issues. The company is currently suspended from trading on Nasdaq since November 2025. In other semiconductor industry news, Baird reported that lead times for various semiconductor segments are continuing to surge, with Onsemi MOSFETs experiencing a lead time of 26 weeks. These developments highlight ongoing shifts in the semiconductor market and corporate strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.